CN1426401A - 新的长效倍他米美类药物(betamimetics)其制备方法,及其作为药物组合物的用途 - Google Patents
新的长效倍他米美类药物(betamimetics)其制备方法,及其作为药物组合物的用途 Download PDFInfo
- Publication number
- CN1426401A CN1426401A CN01808610A CN01808610A CN1426401A CN 1426401 A CN1426401 A CN 1426401A CN 01808610 A CN01808610 A CN 01808610A CN 01808610 A CN01808610 A CN 01808610A CN 1426401 A CN1426401 A CN 1426401A
- Authority
- CN
- China
- Prior art keywords
- compound
- group
- formula
- nitrogen
- carbon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 10
- 239000003814 drug Substances 0.000 title claims abstract description 6
- 239000000808 adrenergic beta-agonist Substances 0.000 title abstract description 5
- 238000004519 manufacturing process Methods 0.000 title abstract description 3
- 230000003454 betamimetic effect Effects 0.000 title abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 20
- -1 dimethylamino, methoxy Chemical group 0.000 claims abstract description 18
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract description 18
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229910052799 carbon Chemical group 0.000 claims abstract description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 6
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims abstract description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 5
- 239000001257 hydrogen Substances 0.000 claims abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 52
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- 239000013543 active substance Substances 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 229960000257 tiotropium bromide Drugs 0.000 claims description 4
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims description 3
- 239000000812 cholinergic antagonist Substances 0.000 claims description 3
- 230000008602 contraction Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 239000000043 antiallergic agent Substances 0.000 claims description 2
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 2
- 208000006218 bradycardia Diseases 0.000 claims description 2
- 230000005796 circulatory shock Effects 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 2
- 230000007794 irritation Effects 0.000 claims description 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 230000002028 premature Effects 0.000 claims description 2
- 230000001823 pruritic effect Effects 0.000 claims description 2
- 230000033764 rhythmic process Effects 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 230000024883 vasodilation Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- MNJNSRQVLNIPFN-UHFFFAOYSA-N 4-[2-[[4-(benzimidazol-1-yl)-2-methylbutan-2-yl]amino]-1-hydroxyethyl]-2-[(4-methoxyphenyl)methylamino]phenol Chemical compound C1=CC(OC)=CC=C1CNC1=CC(C(O)CNC(C)(C)CCN2C3=CC=CC=C3N=C2)=CC=C1O MNJNSRQVLNIPFN-UHFFFAOYSA-N 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000036471 bradycardia Effects 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 229920002261 Corn starch Polymers 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 239000002262 Schiff base Substances 0.000 description 7
- 239000008120 corn starch Substances 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 229960001375 lactose Drugs 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 150000004753 Schiff bases Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- RWRIWBAIICGTTQ-UHFFFAOYSA-N difluoromethane Chemical compound FCF RWRIWBAIICGTTQ-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000002700 tablet coating Substances 0.000 description 2
- 238000009492 tablet coating Methods 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 240000002470 Amphicarpaea bracteata Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- QEVGZEDELICMKH-UHFFFAOYSA-N Diglycolic acid Chemical compound OC(=O)COCC(O)=O QEVGZEDELICMKH-UHFFFAOYSA-N 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- NYYDZOSYLUOKEM-UHFFFAOYSA-N oxaldehyde;hydrate Chemical compound O.O=CC=O NYYDZOSYLUOKEM-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- 229960000797 oxitropium Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Substances [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- H—ELECTRICITY
- H03—ELECTRONIC CIRCUITRY
- H03F—AMPLIFIERS
- H03F2200/00—Indexing scheme relating to amplifiers
- H03F2200/331—Sigma delta modulation being used in an amplifying circuit
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明关于通式1的新颖倍他米美类药物,其中R1是基团(a),其中R3是可被甲氧基任意取代的苄基,R4为氢或R3和R4相连结代表-CO-CH2-CO-桥接,该桥接的羰基连接到氮,R2是选自(b)和(c)的基团,其中R5是二甲氨基,甲氧基或丁氧基,X是一个氮或碳,如X是氮则R6是甲氧苯基或如X是碳则为一稠合的苯基环同时连结到X,本发明也涉及制备所述倍他米美类药物的方法并涉及其作为药物的用途。
Description
本发明关于通式
1的新颖倍他米美类其中R1和R2具有权利要求和说明书中所述的意义,其制备方法以及其作为药物的用途。
发明背景
倍他米美药物(β-肾上腺素能物质)是由现有技术中已知。其可广泛用于各种治疗应用。
为了疾病的药物处置,往往希望制备具有长效持续的药物。通常,要保证在体内长时间达到治疗效果所必要的活性物质浓度,不需要经常重复投药。以较长时间间隔投药活性物质对于患者是很舒适的。
本发明的目的为制备倍他米美类,其特征为活性持续时间较长,因而能够用于制备具有长效的药物组合物。
发明详细说明
意外地发现,上述目的通过通式
1的化合物得到解决。
其中
R3表示苄基,必要时可被甲氧基取代;
R4表示氢
或
R3和R4一起表示-CO-CH2-O-桥接,该桥接的羰基连接到氮,R2表示选自以下的基团:和
其中,
R5表示二甲氨基,甲氧基或丁氧基;
X表示氮或碳,
R6如X为氮则表示甲氧苯基,或者如X为碳则表示一稠合苯基环并也连结到X。
其中
其中,
R5表示二甲氨基,甲氧基或丁氧基;
X表示氮或碳,
R6如X为氮则表示甲氧苯基,或者如X为碳则表示一稠合苯基环,其也连结到X。
优选的通式
1化合物为:其中R1表示R2表示选自以下一基团,和
根据本发明同样重要的式
1化合物为,其中R1表示下基团
其中
R3表示苄基,必要时可被甲氧基取代;
其中
X表示氮或碳,
R6如X为氮则表示甲氧苯基,或如X为碳则表示一稠合苯基环,并也连接到X。
根据本发明尤其重要的为以下式
1表示的化合物:-1-[3-(4-甲氧苄基-氨基)-4-羟苯基]-2-[4-(1-苯并咪唑基)-2-甲基-2-丁氨基]乙醇,-1-[2H-5-羟基-3-氧-4H-1,4-苯并噁嗪-8-基]-2-[3-(4,-N,N-二甲氨苯基)-2-甲基-2-丙氨基]乙醇,-1-[2H-5-羟基-3-氧-4H-1,4-苯并噁嗪-8-基]-2-[3-(4-n-丁氧苯基)-2-甲基-2-丙氨基]乙醇。
根据本发明式
1的化合物中,尤其优选的为其中在上述基团R1的羟基位于氨基取代基的邻位或间位。最好羟基位于氨基的邻位。
本发明的式
1的化合物,视需要可以为个别光学异构体,个别对映异构体或外消旋体的混合物形式,以及游离碱形式或其与药物可接受酸的相应酸的加成盐形式,例如与氢卤酸例如氢氯酸或氢溴酸的酸加成盐,或者与有机酸的加成盐类,如乙酸,草酸,甲酸,二甘醇酸或甲磺酸。
上述酸加成盐中,根据本发明,优选为氢氯酸,甲磺酸和乙酸的盐。
根据本发明化合物可按如下所述制备,部分类似于现有技术中已知的步骤(流程1)。 流程1:
由适当取代的醛
2开始,其必要时可以以其水合物形式存在,与胺
3进行反应而形成式
4的席夫碱(Schiffs base)。从现有技术已知形成席夫碱的方法。这些席夫碱最后经还原而形成本发明式
1的化合物。这还原反应可以类似于已知的标准方法例如以硼氢化钠形式的金属盐氢化物进行。必要时使用保护基(例如苄基保护基)。其使用和其后的去除为专业人员所熟知。
以下所述的合成法实例是用以进一步说明本发明。其仅仅作为步骤的实例,以进一步说明本发明,并非将本发明限制于以下实施例所述。实施例1:1-[2H-5-羟基-3-氧-4H-1,4-苯并噁嗪-8-基]-2-[3-(4,-N,N-二甲氨苯 基)-2-甲基-2-丙氨基]乙醇: 制备席夫碱(式4的化合物)
将19.1克(0.058摩尔)[2H-5-苄氧基-3-氧-4H-1,4-苯并噁嗪-8-基]-乙二醛水合物添加到加热至70℃的250毫升乙醇和9.6克(0.05摩尔)3-(4-N,N-二甲氨苯基)-2-甲基-2-丙胺的溶液中,并搅拌15分钟。冷却后将析出的晶体吸滤并干燥。产率:24克=理论值的99%;熔点=201-204℃。还原席夫碱,得到1-[2H-5-苄氢基-3-氧-4H-1.4-苯并噁嗪-8-基]-2-[3-(4,-N, N-二甲氨基-苯基)-2-甲基-2-丙氨基]乙醇:
将24克席夫碱(0.0495摩尔)悬浮于120毫升乙醇/120毫升二噁烷的混合物中,并在10-20℃于30分钟内与2克NaBH4反应,并搅拌1小时。添加10毫升丙酮后,混合物搅拌30分钟,以300毫升乙酸乙酯稀释,将乙酸乙酯相以约200毫升水清洗二次,以硫酸钠干燥,溶剂真空除去。将醇/丙酮处理残渣,以浓盐酸酸化分离二氢氯化物并吸滤。产率:17.5克=理论值的62.6%;熔点=180-185℃。裂解保护基,得到标题化合物:
将3.5克以上得到的苄基化合物(0.0066摩尔)于75毫升甲醇中在常温和常压下添加0.5克Pd/C进行氢化。吸滤除去催化剂,蒸发滤液,过筛并分离析出的晶体。产率2.4克=理论值的82.8%;熔点=216-218℃(氢氯化物)。实施例2:1-[2H-5-羟基-3-氢-4H-1,4-苯并噁嗪-8-基]-2-[3-(4-n-丁氧苯基)-2- 甲基-2-丙氨基]乙醇:
类似实施例1的方法制备标题化合物。熔点=189-190℃(甲磺酸盐)。实施例3:1-[3-(4-甲氧苄基-氨基)-4-羟苯基]-2-[4-(1-苯并咪唑基)-2-甲基-2- 丁氨基]乙醇:
按类似于实施例1的方法制备标题化合物。熔点=154-155℃(乙酸盐)。实施例4:1-[2H-5-羟基-3-氧-4H-1,4-苯并噁嗪-8-基]-2-[3-(4-甲氧苯基)-2- 甲基-2-丙氨基]乙醇:
按类似于实施例1的方法制备标题化合物。熔点=202-205℃(氢氯化物)。实施例5:1-[2H-5-羟基-3-氧-4H-1,4-苯并噁嗪-8-基]-2-{4-[3-(4-甲氧苯基)-1, 2,4-三唑-3-基]-2-甲基-2-丁氨基}乙醇:
按类似于实施例1的方法制备标题化合物。熔点=175-179℃(氢氯化物)。
正如所发现的,通式
1化合物的特征为其在治疗领域中的用途范围。尤其应该述及的本发明式
1化合物的应用,优选可以作为倍他米美的药物活性而使用。这些包括例如治疗支气管哮喘(支气管肌的松弛),处理COPD的发炎成份,抑制产科中过早发生的宫缩(宫缩抑制),在心房心室阻隔时恢复心脏的窦性心律(sinusthythmus),以及矫正心动徐缓心律紊乱(抗心律不齐药剂),处置循环性休克(血管扩张并提高心-时体积)以及处置搔痒刺激和皮肤发炎。
通式
1化合物可以单独使用或与其它本发明式
1的活性物质组合使用。必要时,通式
1化合物也可以与其它药物活性物质组合使用。这里尤其涉及抗胆碱能物,必要时的其它倍他米美类药物,抗过敏剂,PAF拮抗剂,白三烯拮抗剂和类甾醇类以及其活性物质的组合物。
可以述及的抗胆碱能物的实例包括异丙基阿托品(ipratropium)溴化物,溴乙东莨菪碱(oxitropium)溴化物,特别是替沃托品(tiotropium)溴化物。除本发明化合物外还含有替沃托品(tiotropium)溴化物作为另一活性物质的药剂组合物是尤其优选。这组合物在处置气喘或COPD时,尤为重要,特别是COPD。
式
1化合物给药的适当使用方式包括例如片剂,胶囊,栓剂,液剂等等。药物活性化合物含量应该是组合物总量的0.05至90重量%(优选0.1至50重量%)范围内。例如,合适的片剂可通过混合活性物质与已知赋形剂而制得,例如如碳酸钙,磷酸钙或乳糖的惰性稀释剂,如玉米淀粉或藻酸的崩解剂,如淀粉或明胶的粘合剂,如硬脂酸镁或滑石的润滑剂和/或用以延迟释放用的制剂,如羧甲基纤维素,苯二甲酸纤维素乙酸酯,或聚乙酸乙烯酯。片剂也可以包括多层。
糖衣片剂可通过以正常用于片剂涂层的物质涂布类似片剂制得的核心而制备,例如可力酮(collidone)或虫胶,阿拉伯胶,滑石,二氧化钛或蔗糖。为了达到延迟释放或避免不相容性,核心也可以由多层组成。片剂涂层同样可由多层组成以达到延迟释放,其中也能使用上述用于片剂的赋形剂。
本发明活性物质或活性物质组合物的糖浆可另外含有甜化剂,如糖精,环己烷氨磺酸盐,甘油或糖类及增味剂,例如香精或如香草或柑橘萃取物。另外也可含有悬浮助剂或增稠剂,如羧甲基纤维素钠,湿润剂,如脂肪醇与环氧乙烷的缩合产物,或防腐剂,如对羟基苯甲酸盐类。
液剂以常用方式制备,例如添加等渗剂、防腐剂如对羟基苯甲酸盐,或稳定剂,如乙二胺四乙酸的碱金属盐类,必要时使用乳化剂和/或分散剂,然而,如使用水作为稀释剂,必要时可使用有机溶剂作为溶剂或助溶剂,并转移到注射瓶或安瓿或灌输瓶中。
含一种或多种活性物质或活性物质组合物的胶囊,可以例如通过将活性物质与惰性载体,如乳糖或山梨糖醇进行混合,并将其包装在明胶胶囊内而制备。
适当栓剂可以例如通过和预先准备的载体,如中性脂肪或聚乙二醇或其衍生物混合而制得。
作为助剂可以使用,例如,水,药物可接受的有机溶剂,如石蜡(例如石油馏份),植物基油(例如花生油或芝麻油),单-或多官能醇类(例如乙醇或甘油),载体,如天然岩石粉末(例如高岭土,粘土,滑石,白垩土),合成矿物粉末(例如高度分散的硅酸和硅酸盐),糖(例如蔗糖,乳糖或葡萄糖),乳化剂(例如木质素,亚硫酸盐废碱液,甲基纤维素,淀粉和聚乙烯吡咯烷酮)和润滑剂(例如硬脂酸镁,滑石,硬脂酸和月桂基硫酸钠)。
制剂以常用方法给药,在处置哮喘或COPD时优选为吸入法。关于口服使用的片剂,除了上述载体外,当然还可以包含添加剂,如柠檬酸钠,碳酸钙和磷酸二钙与各种添加剂,如淀粉,优选是马铃薯淀粉,明胶和类似物。此外,制片时可同时使用润滑剂,如硬脂酸镁,月桂基硫酸钠和滑石。水性悬浮液时,除了上述助剂外,活性物质可以掺入各种增味剂或染色剂。
根据本发明化合物剂量是非常取决于给药方式和所治疗的疾病而定。当以吸入方式使用式
1化合物时,以微克范围内的剂量表明为高效力。式
1化合物也可以有效地使用微克范围以上。剂量也可以在克的范围内。
以下实施例和配方例说明本发明而非限定其范围:药物配方实施例 A) 片剂
每片
活性物质 100毫克
乳糖 140毫克
玉米淀粉 240毫克
聚乙烯吡咯烷酮 15毫克
硬脂酸镁
5毫克
500毫克
将细研磨的活性物质,乳糖和部分玉米淀粉混合。将混合物过筛,其后以聚乙烯吡咯烷酮的水溶液湿润,捏和,湿磨并干燥。将颗粒,剩余的玉米淀粉和硬脂酸镁过筛并混合。将混合物压制为适当形状和大小的片剂。B)
片剂
每片
活性物质 80毫克
乳糖 55毫克
玉米淀粉 190毫克
微晶纤维素 35毫克
聚乙烯吡咯烷酮 15毫克
羧甲基钠淀粉 23毫克
硬脂酸镁
2毫克
400毫克
将细研磨的活性物质,部分玉米淀粉,乳糖,微晶纤维素和聚乙烯吡咯烷酮混合,将混合物过筛并以剩余的玉米淀粉和水处理成粒状并将其干燥和过筛。添加羧甲基钠淀粉和硬脂酸镁并混合,将混合物压制成适当大小的片剂。C)
安瓿溶液
活性物质 50毫克
氯化钠 50毫克
注射用水 5毫升
将活性物质于其pH或必要时在pH5.5至6.5下溶于水中,添加氯化钠使其等渗压。将得到的溶液在无热源下过滤,并在无菌状态下将滤液移入安瓿中,其后将其消毒并密封。安瓿含5毫克,25毫克和50毫克活性物质。D)
计量气雾剂
活性物质 0.005
失水山梨糖醇三油酸酯 0.1
单氟三氯甲烷和
二氟二氯甲烷2∶3 添加至100
将悬浮液移至通常的具有计量阀的喷雾容器中。最好每喷一次输送50微升悬浮液。必要时也能以较高剂量(例如0.02重量%)输送。F)
溶液(以毫克/100毫升计)
活性物质 333.3毫克
替沃托品(tiotropium)溴化物 333.3毫克
氯苄烷铵 10.0毫克
EDTA 50.0毫克
HCl(1N) 添加至pH3.4
此溶液能够以通常方法生产。F)
可吸入式粉末
活性物质 6微克
替沃托品(tritropium)溴化物 6微克
乳糖单水合物 添加至25毫克
可吸入式粉末可通过将各成份混合并以常用方法制备。
Claims (17)
7.根据权利要求1的通式
1化合物,特征为,在R1基中的羟基是位于氨基的邻位或间位。
8. 1-[3-(4-甲氧苄基-氨基)-4-羟苯基]-2-[4-(1-苯并咪唑基)-2-甲基-2-丁氨基]乙醇。
9. 1-[2H-5-羟基-3-氧-4H-1,4-苯并噁嗪-8-基]-2-[3-(4,-N,N-二甲氨苯基)-2-甲基-2-丙氨基]乙醇。
10. 1-[2H-5-羟基-3-氧-4H-1,4-苯并噁嗪-8-基]-2-[3-(4-正-丁氧苯基)-2-甲基-2-丙氨基]乙醇。
11.根据权利要求1~10的式
1化合物,其呈个别光学异构体,个别对映异构体的混合物或外消旋异构体形式,以及呈游离碱或其与药理可接受酸的相应酸的加成盐的形式。
12.根据权利要求1~11的通式
1的化合物的用途,其可用作药物。
13.根据权利要求1~11的通式
1的化合物的用途,其可用于制备处置疾病的药物组合物,其中倍他米美类药物具有治疗应用性。
14.根据权利要求1~11的通式
1的化合物的用途,其可用于制备药物组合物以治疗支气管性哮喘(支气管肌的松弛),COPD的发炎成份,抑制产科中过早发生的宫缩(宫缩抑制),在心房心室阻隔时恢复心脏的窦性心律,以及矫正心动徐缓心律紊乱(心律不齐药剂),循环性休克(血管扩张并提高心-时体积)以及搔痒刺激和皮肤发炎。
15.一种药物制剂,其包含一种或多种权利要求1的通式
1化合物作为活性物质,且必要时可以组合常用助剂和/或载体。
16.根据权利要求15的药物制剂,特征为,除了一种或多种式
1化合物外,其也可包含至少一种选自抗胆碱能物、倍他米美类剂、抗过敏剂、PAF拮抗剂、白三烯拮抗剂和类甾醇类的其它活性物质。
17.根据权利要求16的药物制剂,特征为,除了一种或多种式
1化合物外,其也可包含替沃托品(tiotropium)溴化物作为活性物质。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ECSP003424 ECSP003424A (es) | 2000-04-27 | 2000-04-27 | NUEVAS COMPOSICIONES DE MEDICAMENTOS A BASE DE COMPUESTOS ANTICOLINERGICAMENTE ACTIVOS Y ß-MIMETICOS |
ECSP003424 | 2000-04-27 | ||
DE2000151318 DE10051318A1 (de) | 2000-10-17 | 2000-10-17 | Neu, langwirksame Betamimetika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
DE10051318.2 | 2000-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1426401A true CN1426401A (zh) | 2003-06-25 |
Family
ID=40317111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN01808610A Pending CN1426401A (zh) | 2000-04-27 | 2001-04-14 | 新的长效倍他米美类药物(betamimetics)其制备方法,及其作为药物组合物的用途 |
Country Status (23)
Country | Link |
---|---|
US (2) | US20020022625A1 (zh) |
EP (1) | EP1305300A1 (zh) |
JP (1) | JP2003533448A (zh) |
KR (1) | KR20020093083A (zh) |
CN (1) | CN1426401A (zh) |
AR (1) | AR035637A1 (zh) |
AU (1) | AU5629301A (zh) |
BG (1) | BG107120A (zh) |
BR (1) | BR0110331A (zh) |
CA (1) | CA2405745A1 (zh) |
CZ (1) | CZ20023537A3 (zh) |
EA (1) | EA200201056A1 (zh) |
EE (1) | EE200200602A (zh) |
HR (1) | HRP20020845A2 (zh) |
HU (1) | HUP0300832A2 (zh) |
IL (1) | IL152140A0 (zh) |
MX (1) | MXPA02010179A (zh) |
NO (1) | NO20025133D0 (zh) |
NZ (1) | NZ522677A (zh) |
PL (1) | PL362868A1 (zh) |
SK (1) | SK15382002A3 (zh) |
WO (1) | WO2001083462A1 (zh) |
YU (1) | YU79502A (zh) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
US20030229058A1 (en) * | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
US6951888B2 (en) | 2002-10-04 | 2005-10-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions |
DE10246374A1 (de) * | 2002-10-04 | 2004-04-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
DE10253282A1 (de) * | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
US7056916B2 (en) * | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
DE10253220A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
TW200526547A (en) * | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
DE10349850C5 (de) | 2003-10-25 | 2011-12-08 | Clariant Produkte (Deutschland) Gmbh | Kaltfließverbesserer für Brennstofföle pflanzlichen oder tierischen Ursprungs |
TW200531692A (en) * | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
DE102004003428A1 (de) | 2004-01-23 | 2005-08-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Beta-2-Agonisten, und deren Verwendung als Arzneimittel |
US7405232B2 (en) | 2004-02-14 | 2008-07-29 | Boehringer Ingelheim International Gmbh | Long acting beta-2 agonists and their use as medicaments |
WO2005077361A1 (de) * | 2004-02-14 | 2005-08-25 | Boehringer Ingelheim International Gmbh | Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel |
EP1577306A1 (de) * | 2004-03-17 | 2005-09-21 | Boehringer Ingelheim Pharma GmbH & Co.KG | Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen |
US7244728B2 (en) | 2004-03-17 | 2007-07-17 | Boehringer Ingelheim International Gmbh | Long acting betamimetics for the treatment of respiratory diseases |
AU2005235419B2 (en) * | 2004-04-22 | 2010-11-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations containing benzoxazine for treating respiratory diseases |
DE102004019539A1 (de) * | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von Atemwegserkrankungen |
US20050272726A1 (en) * | 2004-04-22 | 2005-12-08 | Boehringer Ingelheim International Gmbh | Novel medicaments for the treatment of respiratory diseases |
US7307076B2 (en) * | 2004-05-13 | 2007-12-11 | Boehringer Ingelheim International Gmbh | Beta agonists for the treatment of respiratory diseases |
EP1595873A1 (de) * | 2004-05-13 | 2005-11-16 | Boehringer Ingelheim Pharma GmbH & Co.KG | Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen |
WO2005110990A1 (de) * | 2004-05-13 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen |
US7220742B2 (en) | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
US20050256115A1 (en) * | 2004-05-14 | 2005-11-17 | Boehringer Ingelheim International Gmbh | Aerosol formulation for the inhalation of beta-agonists |
US20050255050A1 (en) * | 2004-05-14 | 2005-11-17 | Boehringer Ingelheim International Gmbh | Powder formulations for inhalation, comprising enantiomerically pure beta agonists |
DE102004024451A1 (de) * | 2004-05-14 | 2005-12-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten |
US7745621B2 (en) | 2004-05-14 | 2010-06-29 | Boehringer Ingelheim International Gmbh | Long acting bronchodilators for the treatment of respiratory diseases |
DE102004024453A1 (de) * | 2004-05-14 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
MXPA06013916A (es) * | 2004-06-03 | 2007-03-07 | Theravance Inc | Agosnistas del receptor adrenergico beta2 de diamina. |
EP1778638A1 (en) * | 2004-07-21 | 2007-05-02 | Theravance, Inc. | Diaryl ether beta2 adrenergic receptor agonists |
WO2006031556A2 (en) * | 2004-09-10 | 2006-03-23 | Theravance. Inc. | Amidine substituted aryl aniline compounds |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
DE102005007654A1 (de) * | 2005-02-19 | 2006-08-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
CA2618089A1 (en) | 2005-08-08 | 2007-02-15 | Argenta Discovery Ltd. | Bicyclo[2.2.]hept-7-ylamine derivatives and their uses |
GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
PL1917253T3 (pl) * | 2005-08-15 | 2015-06-30 | Boehringer Ingelheim Int | Sposób wytwarzania betamimetyków |
TWI389692B (zh) * | 2005-10-10 | 2013-03-21 | Boehringer Ingelheim Int | 用以吸入β-共效劑的氣溶膠調配物 |
AR058104A1 (es) | 2005-10-21 | 2008-01-23 | Novartis Ag | Compuestos organicos |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
PL2322525T3 (pl) | 2006-04-21 | 2014-03-31 | Novartis Ag | Pochodne puryny do zastosowania jako agoniści receptora adenozyny A<sub>2A</sub> |
EP2051714B1 (de) | 2006-08-07 | 2011-04-13 | Boehringer Ingelheim International GmbH | Arzneimittelkombinationen zur behandlung von atemwegserkrankungen |
US20100222336A1 (en) * | 2006-08-07 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Single enantiomer beta-agonists, methods for the production thereof and the use thereof as medication |
EP2104535B9 (en) | 2007-01-10 | 2011-06-15 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
JP2010518097A (ja) | 2007-02-09 | 2010-05-27 | アイアールエム・リミテッド・ライアビリティ・カンパニー | チャネル活性化プロテアーゼ阻害剤としての化合物および組成物 |
AU2008248598B2 (en) | 2007-05-07 | 2011-11-17 | Novartis Ag | Organic compounds |
MX2010006421A (es) | 2007-12-10 | 2010-06-25 | Novartis Ag | Compuestos organicos. |
BRPI0906838A2 (pt) | 2008-01-11 | 2015-07-14 | Novartis Ag | Pirimidinas como inibidores de quinase |
AU2009256645A1 (en) | 2008-06-10 | 2009-12-17 | Novartis Ag | Pyrazine derivatives as epithelial sodium channel blockers |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
AU2009334597B2 (en) | 2008-12-30 | 2015-07-16 | Pulmagen Therapeutics (Inflammation) Limited | Sulfonamide compounds for the treatment of respiratory disorders |
WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
CA2777245A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
EA201391230A1 (ru) | 2011-02-25 | 2014-01-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов trk |
UY34305A (es) | 2011-09-01 | 2013-04-30 | Novartis Ag | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
ES2882807T3 (es) | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
US9862711B2 (en) | 2014-04-24 | 2018-01-09 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
EA032075B1 (ru) | 2014-04-24 | 2019-04-30 | Новартис Аг | Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы |
ES2761569T3 (es) | 2014-04-24 | 2020-05-20 | Novartis Ag | Derivados aminopiridínicos como inhibidores de fosfatidilinositol 3-cinasas |
WO2020250116A1 (en) | 2019-06-10 | 2020-12-17 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis |
KR20220052934A (ko) | 2019-08-28 | 2022-04-28 | 노파르티스 아게 | 치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도 |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US115681A (en) * | 1871-06-06 | Improvement in water-wheels | ||
US133010A (en) * | 1872-11-12 | Improvement in car-springs | ||
US648621A (en) * | 1899-07-24 | 1900-05-01 | James M Hooper | Strait-jacket. |
DE2540633A1 (de) * | 1975-09-12 | 1977-04-28 | Boehringer Sohn Ingelheim | Neue quartaere n-beta-substituierte benzilsaeure-n-alkyl-nortropinester und verfahren zu deren herstellung |
DE3211185A1 (de) * | 1982-03-26 | 1983-09-29 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue quartaere 6,11-dihydro-dibenzo-(b,e)-thiepin-11-n-alkyl- norscopinether und verfahren zu deren herstellung |
DE3215493A1 (de) * | 1982-04-26 | 1983-11-03 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue zwischenprodukte, verfahren zu ihrer herstellung und ihre verwendung |
US4460581A (en) * | 1982-10-12 | 1984-07-17 | Boehringer Ingelheim Kg | (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones |
US5223614A (en) * | 1987-12-19 | 1993-06-29 | Boehringer Ingelheim Gmbh | New quaternary ammonium compounds, their preparation and use |
DE3743265A1 (de) * | 1987-12-19 | 1989-06-29 | Boehringer Ingelheim Kg | Neue ammoniumverbindungen, ihre herstellung und verwendung |
DE3815480A1 (de) * | 1988-05-06 | 1989-11-16 | Boehringer Ingelheim Kg | Synergistische kombinationen und ihre verwendung als therapeutika |
FR2648709A1 (fr) * | 1989-06-23 | 1990-12-28 | Boehringer Ingelheim France | Nouvelle utilisation de derives de 1-phenyl-2-aminoethanol en tant que moyens cicatrisants |
US5610163A (en) * | 1989-09-16 | 1997-03-11 | Boehringer Ingelheim Gmbh | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
DE4014252A1 (de) * | 1990-05-04 | 1991-11-07 | Boehringer Ingelheim Vetmed | Enantiomerentrennung von cimaterol, (-)-cimaterol und dessen verwendung als arzneimittel oder als leistungsfoerderer |
DE4108393A1 (de) * | 1991-03-15 | 1992-09-17 | Boehringer Ingelheim Kg | Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln |
US5770738A (en) * | 1992-03-05 | 1998-06-23 | Boehringer Ingelheim Kg | Esters of bi- and tricyclic amino alcohols, their preparation and their use in pharmaceutical compositions |
DE19515625C2 (de) * | 1995-04-28 | 1998-02-19 | Boehringer Ingelheim Kg | Verfahren zur Herstellung von enantiomerenreinen Tropasäureestern |
US6506900B1 (en) * | 2001-01-31 | 2003-01-14 | Boehringer Ingelheim Pharma Ag | Process for preparing a scopine ester intermediate |
US7056916B2 (en) * | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
-
2001
- 2001-04-14 PL PL01362868A patent/PL362868A1/xx not_active Application Discontinuation
- 2001-04-14 BR BR0110331-8A patent/BR0110331A/pt not_active Expired - Fee Related
- 2001-04-14 CZ CZ20023537A patent/CZ20023537A3/cs unknown
- 2001-04-14 HU HU0300832A patent/HUP0300832A2/hu unknown
- 2001-04-14 CA CA002405745A patent/CA2405745A1/en not_active Abandoned
- 2001-04-14 KR KR1020027014388A patent/KR20020093083A/ko not_active Application Discontinuation
- 2001-04-14 CN CN01808610A patent/CN1426401A/zh active Pending
- 2001-04-14 EP EP01929560A patent/EP1305300A1/de not_active Withdrawn
- 2001-04-14 SK SK1538-2002A patent/SK15382002A3/sk not_active Application Discontinuation
- 2001-04-14 AU AU56293/01A patent/AU5629301A/en not_active Abandoned
- 2001-04-14 NZ NZ522677A patent/NZ522677A/en unknown
- 2001-04-14 MX MXPA02010179A patent/MXPA02010179A/es unknown
- 2001-04-14 IL IL15214001A patent/IL152140A0/xx unknown
- 2001-04-14 EE EEP200200602A patent/EE200200602A/xx unknown
- 2001-04-14 YU YU79502A patent/YU79502A/sh unknown
- 2001-04-14 JP JP2001580891A patent/JP2003533448A/ja active Pending
- 2001-04-14 EA EA200201056A patent/EA200201056A1/ru unknown
- 2001-04-14 WO PCT/EP2001/004278 patent/WO2001083462A1/de not_active Application Discontinuation
- 2001-04-18 US US09/836,462 patent/US20020022625A1/en not_active Abandoned
- 2001-04-27 AR ARP010101985A patent/AR035637A1/es active Pending
-
2002
- 2002-09-18 BG BG107120A patent/BG107120A/xx active Pending
- 2002-10-24 HR HR20020845A patent/HRP20020845A2/hr not_active Application Discontinuation
- 2002-10-25 NO NO20025133A patent/NO20025133D0/no not_active Application Discontinuation
-
2005
- 2005-02-08 US US11/053,514 patent/US20050137242A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR0110331A (pt) | 2003-01-07 |
JP2003533448A (ja) | 2003-11-11 |
IL152140A0 (en) | 2003-05-29 |
AU5629301A (en) | 2001-11-12 |
YU79502A (sh) | 2006-05-25 |
AR035637A1 (es) | 2004-06-23 |
SK15382002A3 (sk) | 2003-03-04 |
NO20025133L (no) | 2002-10-25 |
US20050137242A1 (en) | 2005-06-23 |
NZ522677A (en) | 2004-10-29 |
CA2405745A1 (en) | 2001-11-08 |
EE200200602A (et) | 2004-04-15 |
EA200201056A1 (ru) | 2003-04-24 |
EP1305300A1 (de) | 2003-05-02 |
NO20025133D0 (no) | 2002-10-25 |
WO2001083462A1 (de) | 2001-11-08 |
KR20020093083A (ko) | 2002-12-12 |
HUP0300832A2 (hu) | 2003-08-28 |
HRP20020845A2 (en) | 2003-10-31 |
PL362868A1 (en) | 2004-11-02 |
MXPA02010179A (es) | 2003-04-25 |
US20020022625A1 (en) | 2002-02-21 |
BG107120A (en) | 2003-05-30 |
CZ20023537A3 (cs) | 2003-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1426401A (zh) | 新的长效倍他米美类药物(betamimetics)其制备方法,及其作为药物组合物的用途 | |
JP5629420B2 (ja) | 新規な抗コリン作用薬、それらの調製方法及び医薬組成物としてのそれらの使用 | |
CN1582278A (zh) | 多晶型rimonabant,其制备方法及含有它的药物组合物 | |
RU2325388C2 (ru) | Новые антихолинергические средства, способ их получения, а также их применение в качестве лекарственных средств | |
EA008665B1 (ru) | Лекарственные средства для лечения хронического обструктивного заболевания лёгких | |
US20040087617A1 (en) | Anticholinergics which may be used as medicaments as well as processes for preparing them | |
EA006966B1 (ru) | Эфиры флуоренкарбоновых кислот, способ их получения, а также их применение в качестве лекарственных средств | |
CN1288147C (zh) | 氟立班丝氨(flibanserin)的稳定多晶体,其制备的技术法及其在药物制备的用途 | |
SK4352003A3 (en) | Novel anticholinergic agents that can be used as medicaments and method for the production thereof | |
CA2501055A1 (en) | Novel betamimetics with extended duration of action, method for production and use thereof as medicaments | |
EA012045B1 (ru) | Бензоксазины для лечения заболеваний дыхательных путей | |
CN1020096C (zh) | 制备咪唑啉衍生物的制备方法 | |
CN100343257C (zh) | 治疗固有活性脱髓鞘炎性病症的ccr1拮抗剂 | |
JPH03151374A (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
TW200526573A (en) | Organic compounds | |
US20050054664A1 (en) | Anticholinergics, processes for preparing them and pharmaceutical composition containing them | |
CN1281453A (zh) | 作为药物的5-[4-[2-(n-甲基-n-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮马来酸盐的水合物 | |
CN1152878C (zh) | 噻唑烷二酮衍生物及其作为抗糖尿病药的用途 | |
US20050234134A1 (en) | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | |
KR20050086821A (ko) | 항콜린성 작용을 하는 카르밤산 에스테르 | |
CN1128030A (zh) | 具有中枢神经系统活性的杂环胺 | |
CA2482637A1 (en) | New esters of hydroxy-substituted nitrogen heterocycles as antagonists of the muscarinic m3 receptor, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions | |
ZA200208658B (en) | Novel, slow-acting betamimetics, a method for their production and their use as medicaments. | |
CN1822837A (zh) | 2-甲氧基甲基-3-(3,4-二氯苯基)-8-氮杂双环[3.2.1]辛烷酒石酸盐 | |
CN1193029C (zh) | 7-氨基吡啶并[2,3-d]嘧啶衍生物,其组合物及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1054027 Country of ref document: HK |